N/A N=47 Randomized Double-blind Basic Science

Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety

Social Intelligence

Bottom Line

View on ClinicalTrials.gov: NCT01551303 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2014

Primary outcome: Primary: Affective Ratings in Affective Learning Task — -0.096; -0.12 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Oxytocin (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Massachusetts General Hospital
Primary completion: Dec 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Affective Ratings in Affective Learning Task	-0.096; -0.12	—

Summary

The purpose of this study is to learn more about how emotional processing may be affected by a hormone called oxytocin. Oxytocin is a hormone that occurs naturally in the body, and may play an important role in the way that the brain perceives information.

Eligibility Criteria

Inclusion Criteria

No current Axis I according to Diagnostic & Statistical Manual for Psychiatry-IV excluded diagnoses as determined by MINI or Structured Clinical Interview for Diagnosis psychiatric diagnostic interview completed within the past 6 months
Age 18 to 65
Subjects must be able to give informed consent and be willing and able to comply with study procedures.

Exclusion Criteria

Patients with severe unstable medical illness, clinically significant laboratory findings, or serious medical illness for which hospitalization may be likely within the next three months
Pregnant or lactating women.
Subjects currently taking hormones, such as estrogen.
Known hypersensitivity to oxytocin or to any of the excipients of Syntocinon Nasal spray.
Known hyponatremia or concurrent use of diuretics.
Subjects with a history of seizure disorder.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01551303). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.